ACE2 and COVID-19: Hence, blocking IL7 signaling may help lower systemic or local ACE2 levels and alleviate SARS-CoV-2 symptoms, providing a scientific rationale for testing anti-IL7 antibodies or IL7 blockers as a treatment for severe COVID-19 patients with advanced age.82 Lastly, repurposing of geroprotective agents to COVID-19 treatment can be a candidate prevention/treatment strategy, especially for vulnerable aged patients.